Jorge Luis Perdomo, Vice Prime Minister of the Republic of Cuba. Author: PL
BEIJING, 2 April. Vice Prime Minister of the Republic of CubaJorge Luis Perdomo, praised the work done by Biotech Pharma (BPL), a joint venture with China in the field of biotechnology, and expressed confidence that they will achieve great results in their future projections.
While visiting the company’s facilities in Beijing, the leader noted that this is one of the most important cooperation projects between the two countries and enjoys the full support of the Caribbean nation. The center manufactures and markets the humanized monoclonal antibody nimotuzumab, manufactured in Cuba and used in the treatment of nasopharyngeal cancer.
He added that in his recent meetings with Chairman of the National Development and Reform Commission of China Zheng Shanjie and Vice President of the National Health Commission Zeng Yixin, he noted the good work of the company.
Perdomo predicted the success of BPL’s development, investment and growth plans, highlighting its great potential to build on the gains made since it opened in 2005 and achieve many more goals in the future.
BPL Chairman Bai Xianhong updated Vice Prime Minister about the achievements of the mixed firm, medium and short term expansion goals, and ongoing research into the use of nimotuzumab in the treatment of other cancers.
In this regard, Maida Mauri, Senior Vice President of BioCubaFarma, said that in addition to its success, Biotech has made a very significant contribution to healthcare in both countries, especially during the Covid-19 pandemic. He recalled that the company supplied nimotuzumab to the island, and thanks to this cooperation, the production facilities of the Center for Molecular Immunology were able to devote themselves to the development of the Sovereign vaccine.
He welcomed the initiatives to expand and explore new indications for monoclonal antibodies, which are highly recognized by the international scientific community, reports PL. Similarly, Mauri rated the performance of the other two Cuban-Chinese joint ventures and open science laboratories in biotechnology cooperation as satisfactory.
Source: Juventud Rebelde